632 related articles for article (PubMed ID: 26922195)
1. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
Cepa M; Vaz C
Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
[TBL] [Abstract][Full Text] [Related]
2. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
[TBL] [Abstract][Full Text] [Related]
3. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
4. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
Santen RJ
J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
[TBL] [Abstract][Full Text] [Related]
5. Practical guidance for the management of aromatase inhibitor-associated bone loss.
Hadji P; Body JJ; Aapro MS; Brufsky A; Coleman RE; Guise T; Lipton A; Tubiana-Hulin M
Ann Oncol; 2008 Aug; 19(8):1407-1416. PubMed ID: 18448451
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.
Gaudio A; Xourafa A; Rapisarda R; Castellino P
Endocr Metab Immune Disord Drug Targets; 2022; 22(3):259-273. PubMed ID: 34370654
[TBL] [Abstract][Full Text] [Related]
7. Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Tang SC
Oncology; 2010; 79(1-2):13-26. PubMed ID: 21051913
[TBL] [Abstract][Full Text] [Related]
8. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.
Hadji P; Aapro MS; Body JJ; Bundred NJ; Brufsky A; Coleman RE; Gnant M; Guise T; Lipton A
Ann Oncol; 2011 Dec; 22(12):2546-2555. PubMed ID: 21415233
[TBL] [Abstract][Full Text] [Related]
9. Potential role of bone-directed therapy on the superiority of aromatase inhibitors over tamoxifen.
Oyan B
Med Hypotheses; 2011 Dec; 77(6):1028-30. PubMed ID: 21930348
[TBL] [Abstract][Full Text] [Related]
10. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
11. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
12. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Perez EA
Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
[TBL] [Abstract][Full Text] [Related]
14. The effects of adjuvant endocrine therapy on bone health in women with breast cancer.
Ramchand SK; Cheung YM; Yeo B; Grossmann M
J Endocrinol; 2019 Jun; 241(3):R111-R124. PubMed ID: 30991355
[TBL] [Abstract][Full Text] [Related]
15. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
16. Osteoporosis management in patients with breast cancer: EMAS position statement.
Trémollieres FA; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; van der Schouw YT; Senturk LM; Simoncini T; Stevenson JC; Stute P; Rees M
Maturitas; 2017 Jan; 95():65-71. PubMed ID: 27802892
[TBL] [Abstract][Full Text] [Related]
17. Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer.
Ghazi M; Roux C
Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):805-11. PubMed ID: 19945692
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
[TBL] [Abstract][Full Text] [Related]
20. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
Safra T; Bernstein-Molho R; Greenberg J; Pelles-Avraham S; Stephansky I; Sarid D; Inbar MJ; Stemmer SM; Geffen DB
Oncology; 2011; 81(5-6):298-305. PubMed ID: 22156381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]